GT Biopharma renews CEO Michael Breen for two-year term, effective April 29, 2025

GT Biopharma, Inc.

CEO Michael Breen's employment renewed for two years from April 29, 2025, with automatic two-year renewals unless 90-day notice given.
Breen continues as Executive Chairman and CEO; may perform duties from UK or elsewhere outside US.
Amendment No. 3 signed August 26, 2025, retroactively effective April 29, 2025.
No other changes to Breen's compensation or benefits under the existing employment agreement.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.